IGF-1 LR3 vs IGF-1 DES research in Canada compares two modified variants of insulin-like growth factor 1 for their differential IGFBP binding properties, receptor activation potency, and pharmacokinetic profiles. Native IGF-1 is tightly regulated by a family of insulin-like growth factor binding proteins (IGFBP-1 through IGFBP-6) that control its bioavailability. Both LR3 and DES modifications reduce IGFBP binding to increase free peptide concentration, but through different structural mechanisms. Canadian growth factor biology researchers use these variants to study the IGFBP regulatory system and IGF-1 receptor pharmacology.
IGF-1 LR3 Research
IGF-1 LR3 (Long Arg3 IGF-1) contains an N-terminal 13-amino acid extension and Glu3→Arg3 substitution that dramatically reduces IGFBP binding affinity (particularly IGFBP-3, the primary circulating IGF-1 carrier). This increases the free fraction of IGF-1 LR3 available for IGF-1R activation, extending its effective half-life to 20-30 hours compared to 12-15 minutes for native IGF-1. Canadian researchers use LR3 to study IGF-1 receptor signalling when IGFBP regulation is removed.
IGF-1 DES Research
IGF-1 DES (Truncated IGF-1, des(1-3) IGF-1) lacks the first three N-terminal amino acids of IGF-1, which are the primary IGFBP binding domain. This truncation produces a peptide with 10× greater potency at the IGF-1R (due to reduced IGFBP sequestration) but shorter half-life. Canadian researchers use DES to study local IGF-1R signalling when IGFBP binding is structurally removed.
Sourcing IGF-1 Variants in Canada
Research-grade IGF-1 LR3 and IGF-1 DES are available from EhBuddy Peptides in Canada. For laboratory research use only.
